Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 1:06 AM
Ignite Modification Date:
2025-12-25 @ 1:06 AM
NCT ID:
NCT05621993
Eligibility Criteria:
Inclusion Criteria:
* Patients with confirmed diagnosis of COVID-19 pneumonia
* Patients with the ability to take medication orally
Exclusion Criteria:
* Severe vomiting and difficulty in taking oral medication or ingestion of drugs after oral administration
* Suspected or confirmed active systemic infection other than COVID-19 pneumonia
* Pregnant or lactating women
* Patients with mental disorders
* Patients with severe liver damage
* Patients who are treated with small molecule drugs such as Nirmatrelvir Tablets/Ritonavir Tablets(co-packaged)
* Patients who are treated with RNA-dependent RNA polymerase (RDRP) inhibitors (Junshipharma VV116, Ascletis Pharma Inc. Asc10, Kexing biopharm Shen26, and Molnupiravir).
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Maximum Age:
75 Years
Study:
NCT05621993
Study Brief:
Protocol Section:
NCT05621993